Patient Safety Must Be Improved

Friday, November 11th, 2011

A new report by the Institute of Medicine calls for more oversight by public and private healthcare facilities in terms of their handling of patient data. It recommends that The Secretary of The U.S. Department of Health and Human Services (HHS) publish a plan within 12 months to minimize patient ...

Parent Training Is Low Risk And Effective For Treating Preschoolers With ADHD

Saturday, October 29th, 2011

A new report from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ) shows that formal training in parenting strategies is a low-risk, effective method for improving preschool-aged children's behavior who are at risk for developing attention deficit hyperactivity disorder (ADHD), whereas using medication ...

XMRV And Related Viruses Not Confirmed In Blood Of Healthy Donors Or Chronic Fatigue Syndrome Patients

Monday, September 26th, 2011

A study supported by the U.S. Department of Health and Human Services could not validate or confirm previous research findings that suggested the presence of one of several viruses in blood samples of people living with chronic fatigue syndrome. The new study also could not find the viruses in blood ...

GERD Treatments, Benefits And Risks – New Report

Monday, September 26th, 2011

New plain-language reports compare the risks and benefits of therapies for gastroesophageal reflux disease (GERD), a digestive condition that affects millions of individuals in the U.S., and can be treated with medications or surgery. The reports are from the U.S. Department of Health and Human Services (HHS) Agency for Healthcare ...

Intercell Starts Trial In Pandemic Influenza With Its Vaccine Enhancement Patch And Provides Update To The Strategic Collaboration With GSK On Patches

Wednesday, May 4th, 2011

Today Intercell AG (VSE: ICLL) announced the start of a further trial in the field of pandemic Influenza, investigating Intercell's adjuvant patch (Vaccine Enhancement Patch - VEP) containing LT (a heat-labile toxin from E. coli) in combination with GSK's H5N1 pandemic antigen. This trial follows prior work with a non-GSK ...